| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701934 | Journal of Thoracic Oncology | 2017 | 36 Pages |
Abstract
EGFR mutation types and subtypes significantly influence survival outcomes in patients with advanced NSCLC who are receiving first-line gefitinib treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Natalia BSc, Shao Weng M.B.B.S., Eng Huat M.B.B.S., Wan Teck M.B.B.S., Ravindran M.B.B.S., Quan Sing M.B.B.S., Amit M.B.B.S., Mei Kim M.B.B.S., Wan Ling M.B.B.S., Chee Keong M.B.B.S., Balram PhD,